Futuximab

Futuximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	HER1
Clinical data
Other names	992 DS
ATC code	none;
Identifiers
CAS Number	1310460-85-5;
ChemSpider	none;
UNII	B37J680LX0;
Chemical and physical data
Formula	C6468H10002N1724O2055S46
Molar mass	146269.94 g·mol−1

Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.^[1] It acts as an immunomodulator and also binds to HER1.^[2]^[3]

This drug was developed by Symphogen.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.

[2] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[3] Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.

[1]

[2]

[3]